The Experts below are selected from a list of 282 Experts worldwide ranked by ideXlab platform

Andrew Naidech - One of the best experts on this subject based on the ideXlab platform.

  • The Five Ps of Acute Ischemic Stroke Treatment: Parenchyma, Pipes, Perfusion, Penumbra, and Prevention of Complications
    The Ochsner journal, 2003
    Co-Authors: Robert A. Felberg, Andrew Naidech
    Abstract:

    Stroke is a treatable disease. Despite the Therapeutic Nihilism of the past, the advent of thrombolysis has changed the way stroke treatment is approached. Acute ischemic stroke is a challenging and heterogeneous disease, and treatment must be based on an understanding of the underlying pathophysiology of ischemia. Interventions are designed to improve neuronal salvage and outcome. The underlying tenets of stroke therapy focus on the brain parenchyma, arterial flow (pipes), perfusion, the ischemic milieu or penumbra, and prevention of complications. This article focuses on the practical issues of ischemic stroke care with a brief review of supporting literature.

  • The 5 Ps of acute ischemic stroke treatment: parenchyma, pipes, perfusion, penumbra, and prevention of complications.
    Southern medical journal, 2003
    Co-Authors: Robert A. Felberg, Andrew Naidech
    Abstract:

    Stroke is a treatable disease. Despite the Therapeutic Nihilism of the past, the advent of thrombolysis has changed the way stroke is approached. Acute ischemic stroke is a challenging and heterogeneous disease. Treatment needs to be based on an understanding of the underlying pathophysiology of ischemia. Interventions are designed to improve neuronal salvage and outcome. The underlying tenets of stroke therapy focus on the brain parenchyma, arterial flow (pipes), perfusion, the ischemic milieu or penumbra, and prevention of complications. This article focuses on the practical issues of ischemic stroke care, with a brief review of supporting literature.

Robert A. Felberg - One of the best experts on this subject based on the ideXlab platform.

  • The Five Ps of Acute Ischemic Stroke Treatment: Parenchyma, Pipes, Perfusion, Penumbra, and Prevention of Complications
    The Ochsner journal, 2003
    Co-Authors: Robert A. Felberg, Andrew Naidech
    Abstract:

    Stroke is a treatable disease. Despite the Therapeutic Nihilism of the past, the advent of thrombolysis has changed the way stroke treatment is approached. Acute ischemic stroke is a challenging and heterogeneous disease, and treatment must be based on an understanding of the underlying pathophysiology of ischemia. Interventions are designed to improve neuronal salvage and outcome. The underlying tenets of stroke therapy focus on the brain parenchyma, arterial flow (pipes), perfusion, the ischemic milieu or penumbra, and prevention of complications. This article focuses on the practical issues of ischemic stroke care with a brief review of supporting literature.

  • The 5 Ps of acute ischemic stroke treatment: parenchyma, pipes, perfusion, penumbra, and prevention of complications.
    Southern medical journal, 2003
    Co-Authors: Robert A. Felberg, Andrew Naidech
    Abstract:

    Stroke is a treatable disease. Despite the Therapeutic Nihilism of the past, the advent of thrombolysis has changed the way stroke is approached. Acute ischemic stroke is a challenging and heterogeneous disease. Treatment needs to be based on an understanding of the underlying pathophysiology of ischemia. Interventions are designed to improve neuronal salvage and outcome. The underlying tenets of stroke therapy focus on the brain parenchyma, arterial flow (pipes), perfusion, the ischemic milieu or penumbra, and prevention of complications. This article focuses on the practical issues of ischemic stroke care, with a brief review of supporting literature.

M. Bragança - One of the best experts on this subject based on the ideXlab platform.

  • depression among cancer patients a reality where Therapeutic Nihilism cannot be accepted
    European Psychiatry, 2017
    Co-Authors: M. Marinho, J. Marques, M. Bragança
    Abstract:

    Introduction Cancer is a life-threatening disease, characterized by a great deal of uncertainty and unpredictability. Thus, several stressors and emotional upheavals pervade the everyday life of cancer patients and can lead to the development of depression. Objectives To review the recent research related to depression in cancer patients. Methods Literature review based on PubMed/MEDLINE, using the keywords “cancer” and “depression”. Results It is estimated that 20–25% of cancer patients meet the criteria for major depressive syndrome at some point in their illness. Depression is associated with a negative impact on treatment adhesion, cancer progression and quality of life, besides increasing suicide risk. However, it is often unrecognized and untreated. Importantly, the mistaken belief that depressive symptoms are expected in this group, the overlap between the neurovegetative symptoms of depression, the somatic symptoms of cancer and its treatment, as well as the effects of comorbid diseases make the diagnosis of major depression so complex in these patients. Some of the most helpful diagnostic indicators are feelings of hopelessness, worthlessness, excessive guilt, loss of self-esteem, and wishes to die. The several risk factors for the development of depression in cancer patients can be divided into four broad categories, namely cancer-related factors, cancer treatment-related factors, psychiatric history, and social factors. Effective management of depression consists in a combination of psychotherapy and psychopharmacology. Conclusion Depression in cancer patients has serious consequences, however appropriate psychiatric intervention can do it over. Thus, its early recognition and appropriate management is imperative.

  • Depression among cancer patients–A reality where Therapeutic Nihilism cannot be accepted
    European Psychiatry, 2017
    Co-Authors: M. Marinho, J. Marques, M. Bragança
    Abstract:

    Introduction Cancer is a life-threatening disease, characterized by a great deal of uncertainty and unpredictability. Thus, several stressors and emotional upheavals pervade the everyday life of cancer patients and can lead to the development of depression. Objectives To review the recent research related to depression in cancer patients. Methods Literature review based on PubMed/MEDLINE, using the keywords “cancer” and “depression”. Results It is estimated that 20–25% of cancer patients meet the criteria for major depressive syndrome at some point in their illness. Depression is associated with a negative impact on treatment adhesion, cancer progression and quality of life, besides increasing suicide risk. However, it is often unrecognized and untreated. Importantly, the mistaken belief that depressive symptoms are expected in this group, the overlap between the neurovegetative symptoms of depression, the somatic symptoms of cancer and its treatment, as well as the effects of comorbid diseases make the diagnosis of major depression so complex in these patients. Some of the most helpful diagnostic indicators are feelings of hopelessness, worthlessness, excessive guilt, loss of self-esteem, and wishes to die. The several risk factors for the development of depression in cancer patients can be divided into four broad categories, namely cancer-related factors, cancer treatment-related factors, psychiatric history, and social factors. Effective management of depression consists in a combination of psychotherapy and psychopharmacology. Conclusion Depression in cancer patients has serious consequences, however appropriate psychiatric intervention can do it over. Thus, its early recognition and appropriate management is imperative.

Jan P. Van Meerbeeck - One of the best experts on this subject based on the ideXlab platform.

  • European guidelines for the management of malignant pleural mesothelioma
    Journal of Advanced Research, 2011
    Co-Authors: Eric Van Thiel, Rabab Gaafar, Jan P. Van Meerbeeck
    Abstract:

    Abstract Malignant Pleural Mesothelioma (MPM) is nearly invariably lethal tumor of the pleura. Significant Therapeutic Nihilism exists among health professionals. Recent progress has reshaped the clinical landscape in the treatment of MPM. Two European guidelines have been published, one from the Task force of the European Respiratory Society (ERS) and the European Society of Thoracic Surgery (ESTS) and the other from the European Society of Medical Oncology (ESMO). With these guidelines and recommendations as a guidepost, this review discusses the major changes and their impact on the management of MPM.

  • European guidelines for the management of malignant pleural mesothelioma
    Polskie Archiwum Medycyny Wewnetrznej, 2010
    Co-Authors: Eric Van Thiel, Jan P. Van Meerbeeck
    Abstract:

    Malignant pleural mesothelioma (MPM) is nearly invariably lethal tumor of the pleura. Significant Therapeutic Nihilism exists among health professionals. Recent progress has reshaped the clinical landscape in the treatment of MPM. Two European guidelines have been published, one from the task force of the European Respiratory Society and the European Society of Thoracic Surgery, and the other from the European Society of Medical Oncology. With these guidelines and recommendations as a guidepost, this review discusses the major changes and their impact on the management of MPM.

Calvin Law - One of the best experts on this subject based on the ideXlab platform.